Trial intelligence / Profile preview

Phase II placebo-controlled dose-finding pilot study of intravenous pixantrone in myasthenia gravis

2007-002817-37Phase 2Active

Sponsor: Carlo Besta Neurological Institute
Start: Jun 2008
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised trial in myasthenia gravis (MG) comparing pixantrone with placebo (2 arms). Primary endpoint: Quantitative Myasthenia Gravis Score. Started Jun 2008; status: active.

Drugs

pixantrone

Conditions

myasthenia gravis (MG)

Beyond the preview

Go deeper on 2007-002817-37.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-002817-37.